Myeloid cell depletion is able to enhance vaccine efficacy since immunization with TLR9 and NOD-2 containing microparticles followed by anti-CD11 treatment further delayed tumor progression in a mouse model of epithelial ovarian cancer [147]. This evidence concerns the gene TLR9 and ovarian carcinoma.